<DOC>
	<DOC>NCT01741688</DOC>
	<brief_summary>This observational study evaluates the use and efficacy of intravenous (IV) tocilizumab in routine clinical practice in participants with moderate to severe rheumatoid arthritis. Eligible participants initiated on tocilizumab treatment in accordance with the local label were followed for 6 months.</brief_summary>
	<brief_title>An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adults, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria Participants in whom the treating physician has made the decision to commence tocilizumab treatment (in accordance with the local label); this can include participants who have received tocilizumab treatment within 8 weeks prior to the enrollment visit Participants who have received tocilizumab more than 8 weeks prior to the enrollment visit Participants who have received treatment with any investigational agent within 4 weeks (or 5 halflives of the investigational agent, whichever is longer) before starting treatment with tocilizumab History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>